Zobrazeno 1 - 10 of 63 pro vyhledávání: '"B. R. Brooks"'
1
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
Autor: S. Duncil, R. Baumhefner, V. Gausche, L. Tvardek, G. Shifroni, E. Cerreta, S. Remo, J. H. Parnell, D. Lefkowitz, S. J. Bird, L. Needham, B. Borowski, M. Shepard, Y. Stark, S. Craig, L. Pardo, T. Vollmer, E. Katz, G. W. Ellison, C Jr Bever, A. C. Tselis, R. Grossman, P. M. Colletti, S. R. Schwid, I. Pinchasi, M. Singh, Staley A. Brod, W. Badger, Andrew D. Goodman, J. B. Guarnaccia, A. Gudusky, H. Panitch, M. A. Burns, J. Tsuruda, Jerry S. Wolinsky, J. W. Rose, D. Lisak, M. Gorbova, C. J. Becker, L. P. Weiner, E. W C Kwok, Dennis L. Kolson, B. Peters, C. Kawai, J. W. Lindsey, N. Carr, I. Vainrub, R. Misnick, K. McCarthy, R. Lewis, M. D. Petrie, J. Flemming, M. Viswanathan, C. Halvorson, K. P. Johnson, P. Turski, G. Sze, O. Khan, B. R. Brooks, D. Ladkani, D. Pfohl, A. Wallace, K. Martin, A. A. Pruitt, Francisco Gonzalez-Scarano, Ponnada A. Narayana, J. Kamholtz, R. Padilla, R. P. Lisak, L. Mannon, S. Kadosh, C. C. Ford, K. Conway, G. Hunter, S. Bhat, S. Jalbut, L. Medina, L. Rosner, L. W. Myers, G. Moore, J. B. Burns, S. Sinha, E. Greinel, J. Garbern, D. A. Shrier, M. Boykins, J. R. Bentson, N. Kachuck, M. Nessaiver
Publikováno v: Multiple Sclerosis. 7:33-41
After the placebo-controlled extension of the pivotal US trial of glatiramer acetate for the treatment of relapsing multiple sclerosis ended, 208 participants entered an open-label, long-term treatment protocol. Magnetic resonance imaging (MRI) was a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0a63205d214a1f405d85fd63875403c
https://doi.org/10.1191/135245801667520627
Zobrazit plný text záznamu
2
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Autor: E. Greinel, I. H. Gomolin, Jerry S. Wolinsky, Suhayl Dhib-Jalbut, David Ladkani, L. R. Rogers, J. Tamulevich, Yafit Stark, B. Gandhi, Staley A. Brod, J. B. Burns, Dennis L. Kolson, Sara G. Austin, K. A. McCarthy, J. W. Rose, S. J. Bird, E. Cerreta, J. H. Parnell, D. Lisak, Kenneth P. Johnson, S. Van Den Noort, L. Smith, L. Pardo, L. W. Myers, J. Guarnaccia, Hillel Panitch, G. W. Ellison, K. L. Conway, Jonathan Goldstein, Christopher T. Bever, C. C. Ford, Andrew D. Goodman, Timothy Vollmer, I. Pinchasi, OA Khan, G. R. Barger, J. W. Lindsey, S. L. Craig, F. J. Vriesendorp, A. Pruitt, B. R. Brooks, M. D. Petri, A. E. Miller, E. Katz, A. McKeon, J. Fleming, C. Kawai, Francisco Gonzalez-Scarano, C. Weasler, W. Mulcahy, A. B. Thomas, S. Reingold, L. P. Weiner, Cris S. Constantinescu, R. P. Lisak, N. Kachuck, D. Pfohl, R. W. Baumhefner, S. Kadosh, M. Dimachkie, D. Mellits
Publikováno v: Scopus-Elsevier
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multiple sclerosis. Of the original 251 patients randomized
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced7b219d8e66817c7bc9a2e3e0fb2c9
https://doi.org/10.1191/135245800678827806
Zobrazit plný text záznamu
3
Correlation of specific virus-astrocyte interactions and cytopathic effects induced by ts1, a neurovirulent mutant of Moloney murine leukemia virus
Autor: Kunal Saha, Ying-Chuan Lin, Paul K.Y. Wong, B. R. Brooks, E. Shikova
Publikováno v: Journal of Virology. 67:1137-1147
ts1 is a highly neuropathogenic and lymphocytopathic mutant of Moloney murine leukemia virus TB (MoMuLV-TB). We previously reported that the primary neuropathogenic determinant of ts1 maps to a single amino acid substitution, Val-25-->Ile, in precurs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc7c4ed209a87a8ff4291277b53b4c8e
https://doi.org/10.1128/jvi.67.3.1137-1147.1993
Zobrazit plný text záznamu
6
Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists
Autor: B R, Brooks, K, Juhasz-Poscine, A, Waclawik, M, Sanjak, D, Belden, K, Roelke, J, Parnell, C, Weasler
Publikováno v: Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7fb01c7919b7babdad980f5554168fa4
https://pubmed.ncbi.nlm.nih.gov/11466959
Zobrazit plný text záznamu
7
Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group
Autor: B R, Brooks
Publikováno v: Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 1
Patient-specific (endogenous) and population-specific (exogenous) risk factor analysis is identifying novel physical and chemical exposures which might be time-linked to the development of amyotrophic lateral sclerosis (ALS) and other motor neuron di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5cb7fbf55a8f0d319d79e3e634e8585c
https://pubmed.ncbi.nlm.nih.gov/11464921
Zobrazit plný text záznamu
8
Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants
Autor: B R, Brooks
Publikováno v: Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 1
The 2nd Consensus Conference (Versailles) recommended that an ALS knowledge-base for initial healthcare providers, diagnosing neurologists and confirming neurologists should be defined to include a simplified version of diagnostic criteria less forma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b80240e177b3f797eae4aa476b2c8003
https://pubmed.ncbi.nlm.nih.gov/11464934
Zobrazit plný text záznamu
9
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group
Autor: K P, Johnson, B R, Brooks, C C, Ford, A, Goodman, J, Guarnaccia, R P, Lisak, L W, Myers, H S, Panitch, A, Pruitt, J W, Rose, N, Kachuck, J S, Wolinsky
Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 6(4)
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone) reduced the relapse rate and slowed accumulation of disability for patients with relapsing - remitting multiple sclerosis. Of the original 251 patients randomized
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::45604bf441cf0c6feebe7f80e7776eb8
https://pubmed.ncbi.nlm.nih.gov/10962546
Zobrazit plný text záznamu
10
Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research
Autor: R G, Miller, T L, Munsat, M, Swash, B R, Brooks
Publikováno v: Journal of the neurological sciences. 169(1-2)
In 1994 consensus guidelines were developed for conducting clinical trials in ALS. With growing experience in clinical trials, it has become clear that a number of further guidelines were needed.Under the auspices of the World Federation of Neurology
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0070619a1c21bd0798946b2ae6c23a40
https://pubmed.ncbi.nlm.nih.gov/10540001
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje